- Home
- CANF vs PMCB Comparison
CANF vs PMCB Comparison
Compare CANF & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- PMCB
- Stock Information
- Founded
- CANF 1994
- PMCB 1996
- Country
- CANF Israel
- PMCB United States
- Employees
- CANF N/A
- PMCB N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CANF Health Care
- PMCB Health Care
- Exchange
- CANF Nasdaq
- PMCB Nasdaq
- Market Cap
- CANF 9.4M
- PMCB 10.5M
- IPO Year
- CANF N/A
- PMCB N/A
- Fundamental
- Price
- CANF $1.54
- PMCB $1.66
- Analyst Decision
- CANF Strong Buy
- PMCB
- Analyst Count
- CANF 2
- PMCB 0
- Target Price
- CANF $14.00
- PMCB N/A
- AVG Volume (30 Days)
- CANF 117.2K
- PMCB 15.7K
- Earning Date
- CANF 02-03-2025
- PMCB 03-17-2025
- Dividend Yield
- CANF N/A
- PMCB N/A
- EPS Growth
- CANF N/A
- PMCB N/A
- EPS
- CANF N/A
- PMCB 0.74
- Revenue
- CANF $667,000.00
- PMCB N/A
- Revenue This Year
- CANF $409.56
- PMCB N/A
- Revenue Next Year
- CANF N/A
- PMCB N/A
- P/E Ratio
- CANF N/A
- PMCB $2.25
- Revenue Growth
- CANF N/A
- PMCB N/A
- 52 Week Low
- CANF $1.29
- PMCB $1.39
- 52 Week High
- CANF $4.69
- PMCB $2.58
- Technical
- Relative Strength Index (RSI)
- CANF 42.93
- PMCB 53.60
- Support Level
- CANF $1.55
- PMCB $1.50
- Resistance Level
- CANF $1.64
- PMCB $1.75
- Average True Range (ATR)
- CANF 0.10
- PMCB 0.11
- MACD
- CANF 0.01
- PMCB 0.01
- Stochastic Oscillator
- CANF 11.76
- PMCB 53.35
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.